Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03

Rein Therapeutics, Inc.

UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
Trial will enroll up to 120 patients globally; two dose groups vs placebo over 24 weeks.
Primary endpoint: safety/tolerability; secondary: lung function and imaging-based fibrosis measures.
Patient recruitment in UK to begin soon; initial data expected in 2026.
LTI-03 is first-in-class, designed to target fibrosis and protect lung regeneration; IPF median survival is 3-5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.